Nintedanib* plus chemotherapy
The LUME-Lung 1 Phase III clinical trial results showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor, extended life by 2.3 months for non-small cell lung cancer (NSCLC) adenocarcinoma patients when added to docetaxel, versus placebo plus docetaxel.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Taxotere